SIOC English
有机化学
高级检索

有机化学 >

2022 , Vol. 42 >Issue 2: 590 - 599

DOI: https://doi.org/10.6023/cjoc202107049

研究论文

新型5位与6位取代的吲唑类衍生物的合成及抗肿瘤活性研究

  • 曹亚权 ,
  • 杨莹雪 ,
  • 翟洪进 ,
  • 王锦 ,
  • 张烁 ,
  • 王焕焕 ,
  • 杨璞 ,
  • 吴春丽
展开
  • a 郑州大学药学院 郑州 450001
    b 新药创制与药物安全性评价河南省协同创新中心 郑州 450001
    c 教育部药物关键制备技术重点实验室 郑州 450001

收稿日期: 2021-07-24

  修回日期: 2021-09-08

  网络出版日期: 2022-02-24

基金资助

国家重点研究开发(2017YFD0501400)

收起

Synthesis and Antitumor Activity of Novel 5- and 6-Substituted Indazole Derivatives

  • Yaquan Cao ,
  • Yingxue Yang ,
  • Hongjin Zhai ,
  • Jin Wang ,
  • Shuo Zhang ,
  • Huanhuan Wang ,
  • Pu Yang ,
  • Chunli Wu
Expand
  • a School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001
    b Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou 450001
    c Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou 450001
* Corresponding author. E-mail:

Received date: 2021-07-24

  Revised date: 2021-09-08

  Online published: 2022-02-24

Supported by

National Key Research and Development Project of China(2017YFD0501400)

Fold

摘要

为了寻找高效低毒的新型抗肿瘤药物, 设计并合成了新型的5位与6位取代的吲唑类化合物. 采用噻唑蓝(MTT)法对目标化合物在PC-3(人前列腺癌细胞)、MCF-7(人乳腺癌细胞)、HepG-2(人肝癌细胞)和MGC-803(人胃癌细胞)四种人类癌细胞的抗增殖活性进行评价. 结果显示大部分化合物对PC-3具有特异性的抗增殖活性. 其中, N-(1-苄基- 1H-1,2,3-三唑-4-基)甲基)-1-异丙基-1H-吲哚唑-5-羧酰胺(8a)和N-[(1-苄基-1H-1,2,3-三唑-4-基)甲基]-1-异丙基-1H-吲唑- 6-甲酰胺(14a)对PC-3细胞的抗增殖活性较好, IC50值分别为6.21和6.43 μmol/L, 为前列腺癌抗肿瘤药物的研究提供了思路.

关键词： 吲唑; 癌症; 抗肿瘤活性; 前列腺癌

本文引用格式

曹亚权 , 杨莹雪 , 翟洪进 , 王锦 , 张烁 , 王焕焕 , 杨璞 , 吴春丽 . 新型5位与6位取代的吲唑类衍生物的合成及抗肿瘤活性研究[J]. 有机化学, 2022 , 42(2) : 590 -599 . DOI: 10.6023/cjoc202107049

Abstract

In order to search for new antitumor drugs with high efficiency and low toxicity, 5- and 6-substituted indazole compounds were designed and synthesized. The antiproliferative activity of target compounds in four human cancer cells, PC-3 (human prostate cancer cell), MCF-7 (human breast cancer cell), HepG-2 (human hepatoma cell) and MGC-803 (human gastric cancer cell), was evaluated by thiazole blue (MTT) method. The results showed that most of the compounds had specific antiproliferative activity against PC-3. Among them, N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1-isopropyl-1H-in- doleazole-5-carboxyamide (8a) and N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1-isopropyl-1H-indoleazole-6-formamide (14a) possess strong antitumor activity against PC-3 with IC50 values of 6.21 and 6.43 μmol/L, respectively. It provides a new idea for the research of anti-tumor drugs for prostate cancer.

Key words： indazole; cancer; antiproliferative activity; prostatic cancer

参考文献

[1]
https://www.iarc.fr/faq/latest-global-cancer-data-2020-qa/
[2]
Xu, K. M.; Chen, R. C.; Schuster, D. M.; Jani, A. B. Urol. Oncol. 2019, 37, 611.
[3]
Zhang, X.; Zhu, Y.; Dong, S.; Zhang, Lu, A.; Li, Y. Y.; Lv, S.; Zhang, J. Life Sci. 2019, 232, 116526.
[4]
Li, J. Y.; Qiao, S.; Li, Y. J.; Wang, J.; Liu, W.; Pan, W. S. Int. J. Biol. Macromol. 2019, 134, 63.
[5]
Zhang, Y.; Rong, D.; Li, B.; Wang, Y. J. Med. Chem. 2021, 64, 7900.
[6]
Cao, Y.; Luo, C.; Yang, P.; Li, P.; Wu, C. Med. Chem. Res. 2020, 30, 501.
[7]
Fabian, L. V.; Lilian, Y. M.; Josel, M. F. J. Biomol. Screen. 2011, 16, 862.
[8]
Tzvetkov, N. T.; Hinz, S.; Küppers, P.; Gastreich, M.; Müller, C. E. J. Med. Chem. 2014, 57, 6679.
[9]
Zhou, J.; Goh, B. C.; Albert, D. H.; Chen, C. S. J. Hematol. Oncol. 2009, 2, 33.
[10]
Cainap, C.; Qin, S.; Huang, W.-T.; Chung, I. J.; Pan, H.; Cheng, Y.; Kudo, M.; Kang, Y.-K.; Chen, P.-J.; Toh, H.-C.; Gorbunova, V.; Eskens, F. A. L. M.; Qian, J.; McKee, M. D.; Ricker, J. L.; Carlson, D. M.; El-Nowiem, S. J. Clin. Oncol. 2015, 33, 172.
[11]
Bellesoeur, A.; Carton, E.; Alexandre, J.; Goldwasser, F.; Huillard, O. Drug Des.,Dev. Ther. 2017, 11, 2801.
[12]
Keating, G. M. Drugs 2015, 75, 1903.
[13]
Yoshida, K.; Takagi, T.; Kondo, T.; Kobayashi, H.; Iizuka, J.; Fukuda, H.; Ishihara, H.; Okumi, M.; Ishida, H.; Tanabe, K. Jpn. J. Clin. Oncol. 2019, 49, 576.
[14]
Chakrapani, C.; Muniappan, M. J. Clin. Diagn. Res. 2016, 10, 01.
[15]
Wong, T. W.; Lee, F. Y.; Yu, C.; Luo, F. R.; Oppenheimer, S.; Zhang, H.; Smykla, R. A.; Mastalerz, H.; Fink, B. E.; Hunt, J. T.; Gavai, A. V.; Vite, G. D. Clin. Can. Res. 2006, 12, 6186.
[16]
Soria, J. C.; Massard, C.; Armand, J.-P.; Andreis, D. D.; Ropert, S.; Lopez, E.; Catteau, A.; James, J.; Marier, J.-F.; Beliveau, R. E. M. J. B. M. Ann. Oncol. 2012, 23, 463.
[17]
Kuntz, K. W.; Campbell, J. E.; Keilhack, H.; Pollock, R. M.; Knutson, S. K.; Porter-Scott, M.; Richon, V. M.; Sneeringer, C. J.; Wigle, T. J.; Allain, C. J.; Majer, C. R.; Moyer, M. P.; Copeland, R. A.; Chesworth, R. J. Med. Chem. 2016, 59, 1556.
[18]
Li, M.; Zheng, N.; Li, J.; Zheng, Y.; Song, W. Green Chem. 2020, 22, 2394.
[19]
Worrell, J. A. M. B. T.; Fokin, V. V. Science 2013, 340, 457.
[20]
Yup, S.; Bae, S.; Seong, D.; Hyung, W.WO 2014/129796, 2014.
[21]
Claudia, F.; Antonella, P.; Yeong, S. K.; Sunmin, L.; Andrea, G.; Marco, D. P.; Anna, T.; Alice, Z.; Michela, C.; Nadia, Z.; Michelandrea, D. C. J. Med. Chem. 2017, 60, 3082.
Options
文章导航

/

〈 〉